Predictive Genetic Testing and Consumer Wellness Genomics Market Trends

Predictive Genetic Testing & Consumer/Wellness Genomics Market Forecast

The Predictive Genetic Testing & Consumer/Wellness Genomics Market is expected to reach USD 5.4 Billion by 2032 at CAGR 11.2% during the forecast period 2023-2032.

Predictive genetic testing is a technique for predicting illness risk in asymptomatic patients. This method involves examining one's Deoxyribonucleic Acid (DNA) for mutations/modifications in living organism genes. It provides precise next-generation platform sequencing results. It aids in examining genetic conditions in the hunt for a cure. Rising awareness of genetic illnesses, Direct-to-Consumer (DTC) availability of genetic test kits, increased R&D investments, and the trend of a healthy lifestyle are all significant factors driving market expansion.

Wide applications of predictive genetic testing & consumer/wellness, rising awareness of genetic illnesses, availability of genetic test kits to Direct-to-Consumer (DTC), high investments in the R&D sector, and increasing trend of healthy living are driving the market. The high prices of predictive genetic testing, on the other hand, may limit the market's growth in predictive genetic testing and consumer/wellness genomics.

COVID-19 Analysis

Drug creation and research activities have increased due to the COVID-19 pandemic, putting additional strain on the healthcare industry. Although the pandemic had a detrimental impact on supply chains and workforces at first, the increased need for innovative treatments has had a favorable impact on market demand overall.

On a regional and global scale, the pandemic has impacted predictive genetic testing. Increased investments in R&D, rising cancer cases, and increased benefits of Next Generation Sequencing (NGS) in cancer research, involvement of new players with innovative ideas, new start-ups in the genomics market every year, and a wide range of applications are all expected to drive the market forward. Cancer, cardiovascular diseases, and several single-gene illnesses are examples. As a result, COVID-19 has had a favorable impact on predictive genetic testing and the consumer/wellness genomics sector.

Market Dynamics

Drivers

• 
  Usage of predictive genetic testing & consumer/wellness genomics in various applications
  
  
  
  • Predictive genetic testing has a wide range of applications, a major growth driver for the predictive genetic testing & consumer/wellness genomics industry. Genetic testing is utilized for various objectives across several industries, including diagnostic testing, presymptomatic and predictive testing, prenatal and newborn screening, genetic carrier testing, pharmacogenetics, testing for cancer therapy recommendations, and tissue typing for plantation.
  
  
  • Furthermore, the demand for predictive testing is increasing as people adopt a healthier lifestyle and become more aware of the benefits of predictive testing. These tests are used to detect disease before it spreads throughout the body. This has a substantial impact on the market's growth.
  
  
  
  


• Rising R&D initiatives for novel therapeutics


• Growing trends of healthy lifestyle patterns

Market Opportunities

• 
  Rise of application in personalized medicine
  
  
  
  • Demand for predictive genetic testing is being driven by increased demand for personalized medicine, rising investments in personalized medicine research, diverse pharmaceutical companies’ involvement, and increasing product approvals. Furthermore, by putting a gene into a living creature, it has replaced traditional therapies and drugs to treat sickness.
  
  
  • The applications of personalized medicine are rising due to its cost-effectiveness, patient compliance, early detection of diseases, drug safety, and optimization of therapies. Advancements in microarray and genetic technologies have propelled personalized medicine. It becomes easy to understand the human genome with the help of a single experiment. As a result, the rise in their demand will fuel future growth in the predictive genetic testing and consumer/wellness markets.
  
  
  
  


• 
  Emerging markets for predictive genetic testing & consumer/wellness genomics
  

Market Restraints

• 
  High cost of genomic research instruments
  
  
  
  • The high costs of predictive genetic testing systems and their components may limit the expansion of the predictive genetic testing and consumer/wellness genomics markets, as purchasing them may be difficult for small and medium-sized businesses and academic institutions. Furthermore, firms typically require many predictive genetic testing sets to attain effective throughput and productivity, which adds to the expenditures.
  
  
  • The expense of keeping the systems running as planned adds to the total cost. Aside from that, businesses must invest in skilled employees that can effectively operate the systems. A scarcity of such trained employees can stifle market expansion.
  
  
  
  


• Inadequate funding and lack of trained professionals


• Complexity in the genetic testing process

Value Chain Analysis

The global predictive genetic testing & consumer/wellness genomics market is projected to exhibit significant growth over the forecast period, which can be attributed to factors such as the various applications of testing and increasing R&D initiatives. The value chain analysis for the market comprises five major components, which start with research & product development, followed by the manufacturing of the products, distribution & sales, and ends with post-marketing surveillance.

Segment Overview

By Test Type

• Predictive Testing

Predictive testing is becoming more popular because of various variables, including the rising prevalence of genetic disorders, the demand for genetic counseling, and the growing popularity of healthy lifestyle habits. Genetic counseling is a treatment that entails disseminating information about genetic illnesses to persons affected by them. Breast and ovarian cancer, colorectal cancer, Alzheimer's disease, multiple endocrine neoplasia type 2, and hemochromatosis are among the disorders for which it has been used. It is a low-cost, high-efficiency purification process with great precision. Predictive testing can also be tweaked to satisfy the needs of personalized medicine, such as drug safety and cost-effectiveness, which will drive up demand for the category.

Predictive testing held the largest share in the market in 2020 due to its wide applications in genetic disorders.

• Consumer Genomics

Consumer genomics is growing in popularity as more people use genealogy services, which provide precise information on relatives and their diseases. Customers and physicians are becoming more aware of genealogical services, and this information is being disseminated to patients. The spread of genetic kits to Direct-to-Consumer (DTC) is propelling the consumer genomics sector. The inexpensive cost of various testing kits also promotes the expansion of predictive genetic testing and consumer/wellness genomics.

Companies are offering paternal and maternal kits, such as FamilyTree DNA (California), AncestryDNA (US), 23andMe, Inc. (US), and MyHeritage (Israel). Moreover, some companies providing food plans and diet services including are My Gene Diet (Australia), Smart DNA (Sweden), and Halo Health International (US).

• Wellness Genomics

The market is growing because of increased knowledge of genetic illnesses, healthcare, economical sequencing, and lower kit costs. Several bioinformatics companies offer services such as DNA-based information management or detect wellness; even those who want a career in sports can get information related to genomes to treat aging.

By Application type

• Breast & Ovarian Cancer

Breast and ovarian cancer are serious diseases that are more prevalent in industrialized areas. Breast cancer cases are expected to increase by 10 to 12 percent per year. The incidence of ovarian cancer is far lower than that of breast cancer. The incidence of ovarian cancer, on the other hand, is increasing. Predictive genetic testing to provide information on favorable and negative medical, social, and psychological implications has been distressing to the American Society of Clinical Oncology (ASCO). Biomarker genetic testing is used to diagnose breast and ovarian cancer. It detects gene-gene and gene-environment interaction. BRCA1 and BRCA2 are two pre-tests to detect breast and ovarian cancer. These are driving the market due to affordable price, Direct-to-Customer Service (DTC), and providing both the data such as medical decisions and family planning. Moreover, the rising prevalence in the US is leading the market towards growth.

Breast & ovarian cancer is predicted to have the highest CAGR during the forecast period.

• Cardiovascular Screening

The instrument cardiac biomarker can diagnose Cardiovascular Disease (CVD). Cardiac biomarkers are protein molecules released into the bloodstream when a person experiences a heart issue. It makes a forecast about the patient's risk level. Myocardial infarction, congestive heart failure, and acute coronary syndrome are all cardiovascular disorders. Troponin, Creatine Kinase-muscle/Brain (CK-MB), B-type, natriuretic, peptide, and high sensitivity C reactive protein are examples of CVD testing. The increase in the number of people suffering from various types of cardiac illnesses, as well as the growing elderly population, are driving the market forward.

Furthermore, key factors to drive the market include the rising prevalence of acute coronary artery disease, congestive heart failure, and myocardium infarction.

• Colon Cancer

Multiple polyps are present in the Gastrointestinal Tract (GIT) in colon cancer. Hereditary Nonpolyposis Colon Cancer (HNCC) is the most common autosomal inheritance colon cancer. Because of the high prevalence, this is driving the colon cancer market. 

• Others

Other diseases, including Parkinson's/Alzheimer’s disease, urologic screening/prostate cancer screening, orthopedic & musculoskeletal, and diabetic screening and monitoring, are driving the growth of the predictive genomic and consumer/wellness genomics market.

By Setting Type

• Proteomic Testing

By the end of the forecast year, the proteomic market is predicted to generate USD 5,590 million in revenue. The rise in R&D investment, high prevalence, increased government financing, customized medicine research, and medication discovery are important factors driving the growth of the predictive genomic testing and consumer/wellness genomics markets. Cancer, infectious illnesses, diabetes, neurological disorders, immunological diseases, cardiovascular diseases, and other clinical diagnostic applications are expected to boost the market.

• Metabolic Testing

The metabolic testing market is growing at a healthy CAGR due to the high prevalence of lifestyle diseases, which fuels the growth of the market. Some other pivotal factors include the advancement of technology, increased healthcare expenditure, growing R&D sector, government initiatives, and rising standard of living, which is driving the growth of the predictive genomic testing and consumer/wellness genomics market.

• Genomic Testing

Genomic testing kits or panels are available in the market to detect inherent diseases in living organisms. The detection procedure begins with collecting samples, which are then sent to a laboratory for analysis. During the forecast period, it is expected to increase significantly. Prenatal & neonatal testing, diagnostic testing, genetic disease identification, pharmacogenomic testing, and predictive & presymptomatic testing are additional test kits utilized in testing. The rising awareness, increased research in personalized medicine, and rising prevalence of genetic disorders are the major growth drivers to hit the market at its peak.

Regional Analysis

The predictive genetic testing & consumer/wellness genomics market based on the region has been segmented into North America, Europe, Asia-Pacific, and the rest of the world.

North America

The presence of key players, rising prevalence of chronic disease, and increasing R&D initiatives for novel therapeutics, well-established healthcare infrastructure, and adoption of advanced technologies is fueling the growth of the predictive genetic testing & consumer/wellness genomics market in North America.

The North American region, comprising the US and Canada, held the largest market share in 2020. Owing to factors such as developed healthcare infrastructure and key players in the region driving growth through novel product launches, expansion, and acquisitions. For instance, in 2021, Illumina (US) collaborated with Helix OpCo (US) to create a nationwide surveillance infrastructure in the US with the support of the CDC to track the emergence and prevalence of developing SARS-CoV-2 strains. Furthermore, the rising cases of Non-communicable Diseases (NCDs) in the region are increasing the demand for more effective therapeutics that supplement growth for the predictive genetic testing & consumer/wellness genomics market. According to the American Cancer Society, in 2020, an estimate revealed that 1.8 million new cases of cancer were diagnosed, and 606,520 cancer deaths were recorded.

Asia-Pacific

Improving healthcare infrastructure, high prevalence of chronic diseases, and rising R&D expenditure, growth in population, increase in disposable income, demands of genetic testing kits, and government funding are anticipated to drive the market growth in the region.

The Asia-Pacific region is expected to show the significant CAGR during the forecast period. This is due to factors like the presence of emerging economies and well-established healthcare infrastructure, making the utilization of predictive genetic test more feasible and accessible. Furthermore, the region's rising R&D spending helps to support the market. For instance, according to the American Association for the Advancement of Science (AAAS), in March 2021, China is predicted to surpass the US as the global leader in R&D spending in 2019, with its R&D investment increasing by 13% compared to 8% in the US.

Additionally, key players are expanding operations in this region, further providing growth for the market. For instance, ARUP Laboratories (US), Genesis Genetics (Michigan), Pathway Genomics (US), Color Genomics Inc. (US), Bureau Gravimétrique International (China), and Myriad Genetics, Inc. (US) are operating to the predictive genetic testing & consumer/wellness genomics.

Competitive Landscape

The industry players are adopting several business strategies to increase their market presence. They are significantly investing in R&D activities to expand their product portfolio, further driving the predictive genetic testing & consumer/wellness genomics market. In addition, the market players are adopting several strategic initiatives such as new product launches, contractual agreements, mergers, and acquisitions, increasing investments, and partnering with other players to expand their global footprint.

One of the key market players, 23andMe, Inc (California), was founded in 2006. Genetic research, consumer genetics, Direct-to-Consumer (DTC) genetic testing, and other services are offered by the company. They have a wide range of predictive test kits in their product offering. In January 2021, the company collaborated with Medscape (New York) and found that physicians are comfortable providing direct-to-consumer services.

List of companies covered in this report:

• 23andMe, Inc. (California)


• Myriad Genetics, Inc. (US)


• Hoffmann-La Roche Ltd. (Switzerland)


• Abbott Laboratories (US)


• Genesis Genetics (US)


• Agilent Technologies (US)


• Thermo Fisher Scientific, Inc. (US)


• Bureau Gravimétrique International (China)


• Bio-Rad Laboratories Inc. (US)


• Illumina, Inc. (US)


• Counsyl, Inc. (California)


• ARUP Laboratories (US)


• Others

Recent Developments

• In June 2021, Bio-Rad Laboratories, Inc. (US), Bioaster (France), and Genetic Analysis (Norway) partnered to provide genetic metabolic disorders on the microbiome. This augments the growth of the predictive genetic testing & consumer/wellness genomics


• In August 2020, Thermo Fischer Scientific introduced an Oncomine Myeloid Assay GX that enables users to identify biomarkers associated with myeloproliferative neoplasm by detecting over 600 fusion isotypes. This product has contributed to the market's expansion.


• In July 2020, 23andMe, Inc (California) collaborated with the giant GlaxoSmithKline (UK) to provide a genetic database of approximately ten million populations searching for cancer information. This added value and further fuels the growth of the predictive genetic testing & consumer/wellness genomics


• In February 2020, Bureau Gravimétrique International (China) signed an agreement with giant distributors in Brazil, Argentina, Peru, Ecuador, Colombia, and Mexico. The partnership paves the way for the company to extend its DNA sequencing and laboratory automation offerings in Latin America.


• In June 2019, Thermo Fisher Scientific Inc. (US) entered into a global research collaboration with predictive laboratories to concentrate on women's infertility via genetic factors. It is taking advantage of the market's apex.

Report Overview

The study covers the existing short-term and long-term market effects. It helps decision-makers to draught short-term and long-term business plans by region. The report covers major regions in North America, Europe, Asia-Pacific, and the Rest of the World. The report analyzes market drivers, restraints, opportunities, challenges, Porter's five forces, value chain, and the impact of COVID-19 on the market.

Study Objectives

• To provide a detailed analysis of the market structure and forecast for the next seven years of the various segments and sub-segments of the predictive genetic testing & consumer/wellness genomics


• To provide insights about factors affecting the market growth.


• To analyze the predictive genetic testing & consumer/wellness genomics market based on various factors- price analysis, supply chain analysis, Porter's five force analysis, etc.


• To provide historical and forecast revenues of the market segments and sub-segments with respect to four main geographies and their countries- North America, Europe, Asia-Pacific, and the Rest of the World.


• To provide a country-level analysis of the market with respect to the current market size and future prospective.


• To provide a country-level analysis of the market for segments by test type, application, and setting type


• To provide strategic profiling of key players in the market, comprehensively analyze their core competencies, and draw a competitive market landscape


• To track and analyze competitive developments such as joint ventures, strategic alliances, mergers & acquisitions, new product developments, and R&D in predictive genetic testing & consumer/wellness genomics market

Market Segmentation:

Global Predictive Genetic Testing & Consumer/Wellness Genomics Market, by Test Type

• Predictive Testing
  
  
  
  • Genetic Susceptibility Test
  
  
  • Predictive Diagnostic
  
  
  • Population Screening
  
  
  
  


• Consumer Genomics


• Wellness Genomics
  
  
  
  • Nutria Genetic
  
  
  • Skin & Metabolism Genetics
  
  
  • Others
  
  
  
  

Global Predictive Genetic Testing & Consumer/Wellness Genomics Market, by Application

• Breast & Ovarian Cancer


• Cardiovascular Screening


• Diabetic Screening & Monitoring


• Colon Cancer


• Parkinsonism/Alzheimer’s Disease


• Urologic Screening/Prostate Cancer Screening


• Orthopedic & Musculoskeletal


• Others

Global Predictive Genetic Testing & Consumer/Wellness Genomics Market, by Setting Type

• Proteomic Testing


• Metabolic Testing


• Genomic Testing

Global Predictive Genetic Testing & Consumer/Wellness Genomics Market, by Region

• North America
  
  
  
  • US
  
  
  • Canada
  
  
  
  


• Europe
  
  
  
  • Germany
  
  
  • France
  
  
  • UK
  
  
  • Italy
  
  
  • Spain
  
  
  • Rest of Europe
  
  
  
  


• Asia-Pacific
  
  
  
  • China
  
  
  • Japan
  
  
  • India
  
  
  • Australia
  
  
  • South Korea
  
  
  • Rest of Asia-Pacific
  
  
  
  


• Rest of the World
  
  
  
  • Middle East
  
  
  • Africa
  
  
  • Latin America
  
  
  
  

Intended Audience

• Genetic testing kit or panel manufacturers and suppliers


• World Health Organization (WHO)


• Research and Development (R&D) Companies


• Biopharmaceutical and pharmaceutical Companies


• Government & Independent Research Laboratories


• Government and Independent Regulatory Authorities


• Market Research and Consulting Service Providers


• Academic Institutes and Universities